Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Immunomedics Fell as Much as 10.8% Today

By Maxx Chatsko - Updated Nov 8, 2018 at 3:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A handful of updates heading into a critical regulatory review date had investors reconsidering a healthy market cap.

What happened

Shares of Immunomedics (IMMU) fell nearly 11% today after the company reported fiscal first-quarter 2019 operating results. Immunomedics is a pre-commercial business, so there's not much for investors to peer into except, perhaps, the magnitude of operating losses accrued as the company attempts to transition to a commercial-stage entity.

On that note, the business racked up an operating loss of $57.1 million in the most recent quarter. That compares to an operating loss of $21.6 million in the year-ago period, although nearly all of the difference can be explained by an increase in research and development (R&D) spending for the company's maturing pipeline and preparation for the potential approval and market launch of its first product.

As of 3:28 p.m. EST, the stock had settled to an 8.8% loss.

A yellow descending line in front of a black and white stock chart.

Image source: Getty Images.

So what

Immunomedics stock has risen over 100% in the last year on the heels of promising data from clinical trials investigating sacituzumab govitecan as a potential treatment for various solid tumors. The company filed a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) seeking regulatory approval for the drug as a treatment in metastatic triple-negative breast cancer (mTNBC). The application was accepted months ago, and now investors are simply waiting for a regulatory decision on Jan. 18, 2019 -- hoping for approval.

Therefore, swelling operating expenses are not surprising by any means given the circumstances. However, Immunomedics noted in its press release that it was working "closely and collaboratively with the FDA to address outstanding review issues" regarding its BLA for its lead drug candidate. The mention of "outstanding review issues" may have spooked investors, but it's more likely referring to the stricter regulatory guidelines for biologic drugs than to something that unexpectedly occurred.

Additionally, Immunomedics announced that it had expanded its current collaboration with AstraZeneca to include metastatic non-small cell lung cancer indications. Financial terms of the expanded deal, if there were any, were not disclosed.

Now what

Despite the dramatic one-day loss, there doesn't appear to be much reason for long-term investors to worry just yet. Immunomedics remains on track for receiving a regulatory decision for its first product in early January 2019, has continued to investigate the drug's use in additional clinical trials, and even signed a long-term manufacturing contract with Samsung Biologics in September that will see the company fork over $82 million in the next three years for key components of the final drug product. Long story short, nothing has changed today for those thinking about the long-term potential of sacituzumab govitecan.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Immunomedics, Inc. Stock Quote
Immunomedics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.